US Tiger Securities Sticks to Its Buy Rating for XPeng, Inc. ADR (XPEV)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Pei CFA is ranked #9697 out of 9921 analysts.
In addition to US Tiger Securities, XPeng, Inc. ADR also received a Buy from Bank of America Securities's Ming-Hsun Lee in a report issued today. However, on August 11, Bernstein maintained a Hold rating on XPeng, Inc. ADR (NYSE: XPEV).
The company has a one-year high of $27.16 and a one-year low of $6.65. Currently, XPeng, Inc. ADR has an average volume of 6.99M.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
36 minutes ago
- Business Insider
Buffett's Endorsement Isn't Enough to Sway Bank of America on UNH Stock
UnitedHealth (NYSE:UNH) stock grabbed headlines last week, as Warren Buffett – the legendary Oracle of Omaha – disclosed a $1.6 billion stake, a move that immediately caught Wall Street's attention. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. After a brutal stretch in 2025 marked by a 50% plunge in the stock due to soaring medical costs, regulatory scrutiny, leadership upheaval, and withdrawn earnings guidance, Buffett's investment stood out as a vote of confidence that helped spark a rally in UNH shares. More importantly, given Buffett's oft-repeated mantra that his favorite holding period is 'forever,' the move carries the weight of a long-term endorsement – particularly in a sector where Berkshire has decades of experience. Still, not everyone sees Buffett's buy as a signal for investors to rush in. Bank of America analyst Kevin Fischbeck agrees that it's a 'positive sign,' but cautions that few retail investors share Buffett's time horizon. 'If you can take a 5-year view, you likely will do well,' Fischbeck notes, 'but few investors have that investment horizon, and those that do, still want to see positive returns each year over that time.' That tension between Buffett's timeless patience and Wall Street's year-to-year reality is where Fischbeck sees trouble. The analyst argues that UNH's path higher is unlikely before 2027, pointing to three key uncertainties that could weigh on performance. Any negative outcome, he warns, could delay meaningful upside by a full year. The first question centers on whether earnings have reached a new baseline. Fischbeck believes they have, stabilizing around $16.80 to $17.00 for the year ahead – modest growth from UNH's $16.00 forecast for 2025. Achieving that range would mark progress, but hardly the kind of surge investors might hope for. The second concern is UNH's Medicare Advantage (MA) membership and the percentage that qualifies for a 5% quality bonus. 'Stars performance can make or break MA profitability,' Fischbeck stresses, warning that management missteps could leave UNH at risk of falling below industry norms – a 'negative surprise' when CMS data is released in mid-October. However, the biggest risk the analyst identifies revolves around a potential 2027 MA coding adjustment. This is not just a risk for the upcoming year, but will remain an open issue in 2027 as well. 'A new coding adjustment… could easily wipe out the progress UNH makes in coming years,' adds Fischbeck, who estimates that the last coding adjustment ended up costing UNH some $16 billion in revenues. Amid this 'significant uncertainty,' Fischbeck remains cautious, assigning UNH shares a Neutral rating even as he raises his price target from $290 to $325 – implying an 8% upside. (To watch Fischbeck's track record, click here) The broader Wall Street view, on the other hand, offers a slightly more upbeat prognosis. With 18 Buys, 2 Holds, and 2 Sells, UNH boasts a Moderate Buy consensus rating. (See UNH stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Business Insider
36 minutes ago
- Business Insider
Nexon Stock Slips on AI Ad Image Theft Accusations
Nexon (JP:3659) stock was down on Wednesday alongside allegations that the video game company stole the likeness of a popular streamer to promote its game, The First Descendant. Twitch streamer DanieltheDemon, who has over 78,000 followers, has released a public statement saying that he has nothing to do with the game and isn't involved in its promotion. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. DanieltheDemon was prompted to release this statement following a new ad campaign that went live over the weekend. In one of those videos, a streamer that looks incredibly similar to DanieltheDemon praises the game. However, upon closer inspection, this appears to be a video made or edited with artificial intelligence (AI). DanieltheDemon stated, 'I have no affiliation nor contract with The First Descendant. They stole my face/reactions from my most viral video and used AI to change what my mouth says and a voice that isn't mine. I did not consent for my likeness to be used.' What This Means for Nexon Stock It's unclear what this means for Nexon stock. There's been no talk about a lawsuit at this time, meaning the company might not face legal action over its alleged theft of DanieltheDemon's appearance. However, the move could still earn it the ire of his fans, as well as the larger internet. With AI in its early stages, there are significant concerns about its uses. Using it to make someone say or support something they didn't likely wouldn't sit well with many. As for Nexon stock, the shares were down 0.48% when the Tokyo Stock Exchange closed on Wednesday. Even so, the company's stock has rallied 41.91% year-to-date and 11.83% over the past 12 months. Is Nexon Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Nexon is Hold, based on one Buy and three Hold ratings over the past three months. With that comes an average Nexon stock price target of ¥2,952.80, representing a potential 22.57% downside for the shares.
Business Insider
36 minutes ago
- Business Insider
Macquarie Remains a Buy on Dexus (DEXSF)
Macquarie analyst maintained a Buy rating on Dexus today and set a price target of A$7.96. The company's shares closed last Friday at $4.51. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Macquarie, Dexus also received a Buy from UBS's Tom Bodor in a report issued yesterday. However, today, Morgan Stanley maintained a Sell rating on Dexus (Other OTC: DEXSF). Based on Dexus' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $560.2 million and a net profit of $10.3 million. In comparison, last year the company earned a revenue of $511 million and had a GAAP net loss of $597.2 million
